Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Qlife – Takeaways from Q2 interview with CFO Kasper Rousøe.

By Claus ThestrupCEO, Sweden
Qlife Holding

Qlife – Takeaways from Q2 interview with CFO Kasper Rousøe.

Qlife soft launched their CRP assay earlier this year in Ireland and the UK. The CFO Kasper Rousøe confirmed sales is backend loaded and should start to show up in 2024.

Qlife initiated a restructuring program in autumn 2022 and during 2023 added additional areas to take out costs. Staff reductions are already completed. The CFO expect full impact from cost initiatives in Q4-2023. Qlife will get back with future run rate on costs later this year.

Aidian arbitration case – CFO confirmed that Finish Arbitration Institution accepted Qlife’s counter claim.

Listen to the Q2 interview with CFO Kasper Rousøe here: Interview with CFO

Regarding Egoo Innovate read our latest update on the company here: Egoo Innovate

Disclaimer:

HC Andersen Capital receives payment from Qlife for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup 08:00 AM 25-08-2023.

Qlife Holding AB is a med-tech group that strives to revolutionize the market for clinical biomarkers and virus tests. By enabling tests at home as a complement to tests in healthcare, access to important health information is facilitated, which can contribute to better treatment and potentially prevent diseases. The first capsules in the company's product, Egoo.Health Platform, were CE-marked for professional use in early 2020. The company has patent protection for key parts of its technology. The Danish-based company is listed on Nasdaq First North Stockholm.

Read more on company page
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.